Stent-Assisted Angioplasty of Symptomatic Intracranial Vertebrobasilar Artery Stenosis: Feasibility and Follow-up Results by 源��룞�씡 et al.
Stent-Assisted Angioplasty of Symptomatic
Intracranial Vertebrobasilar Artery Stenosis:
Feasibility and Follow-up Results
Dong Joon Kim, Byung Hee Lee, Dong Ik Kim, Won Heum Shim, Pyoung Jeon, and
Tae Hong Lee
BACKGROUND AND PURPOSE: The natural history of symptomatic, untreated posterior
circulation stenosis is dismal, with many patients experiencing significant morbidity or mor-
tality. The purpose of this study was to evaluate the feasibility and results of stent-assisted
angioplasty of symptomatic intracranial vertebrobasilar artery stenosis.
METHODS:We reviewed the imaging findings and medical records of 17 consecutive patients
who were treated with stent-assisted angioplasty for medically refractory vertebrobasilar artery
stenosis. The location of the lesion, degree of stenosis, procedure-related complications, and
clinical and short- and long-term angiographic results were assessed.
RESULTS: The population included 17 cases (10 men, seven women; age range, 51–74 years;
mean, 64 years). The locations of the lesions were intracranial vertebral artery (n  13) and
basilar artery (n  6). The mean degree of stenosis decreased from 76.1  14.6% before
stent-assisted angioplasty to 1.3  2.8% (P < .05) after the procedure. Acute in-stent throm-
bosis developed in one case (6%, Mori type B lesion), which was successfully treated with
intraarterial abciximab infusion and angioplasty. Another patient (6%, Mori type C lesion)
developed immediate postprocedural transient diplopia and ataxia, which gradually resolved.
No other patient showed symptoms related to the vertebrobasilar artery lesion at follow-up. No
significant restenosis was observed at short-term (five patients; follow-up range, 0.5–6 months;
mean, 4.3 months) or long-term (six patients; follow-up range, 12–41 months; mean, 21
months) angiographic follow-up.
CONCLUSION: Stent-assisted angioplasty is a feasible treatment method for vertebrobasilar
artery stenosis. The patency of the stent-assisted angioplasty seems to be preserved in the
long-term, with good clinical outcome.
The natural history of untreated posterior circulation
stenosis is dismal, with many patients experiencing
significant morbidity or mortality (1–3). Retrospec-
tive data suggest that the annual stroke rates for
patients with symptomatic intracranial vertebral or
basilar artery stenosis are 7.8% and 10.7%, respec-
tively, despite anticoagulation or antiplatelet therapy
(3).
Recently, percutaneous transluminal angioplasty
was proposed as a promising alternative treatment for
patients with intracranial atherosclerotic stenosis
symptoms despite medical therapy. However, percu-
taneous transluminal angioplasty has had the prob-
lems of dissection, elastic recoil, and thrombosis (4,
5). In a series of 42 cases of angioplasty for intracra-
nial stenosis by Mori et al (4), the 1-year angiographic
restenosis rate in type A (short, 5 mm in length,
concentric or moderately eccentric lesions not totally
occlusive), type B (tubular, 5–10 mm in length, ex-
tremely eccentric or totally occluded lesions, 3
months old), and type C (diffuse, 10 mm in length,
extremely angulated [90°] lesions with excessive tor-
tuosity of the proximal segment, or totally occluded
lesions, and 3 months old) lesions were 0%, 33%,
and 100%, respectively, with cumulative risk of fatal
or nonfatal ipsilateral ischemic stroke in 8%, 12%,
56%, respectively, at 1 and 2 years.
Stent-assisted angioplasty has been limited mainly
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by the apprehension concerning the technical feasi-
bility, periprocedural complications, and short- and
long-term outcomes (6). Major problems still exist;
nonetheless, recent technical advances in instruments
used for angioplasty and stent placement have al-
lowed easier trackability through the small and tortu-
ous intracranial vessels. Also, experience from the
earlier works of intracranial angioplasty and stent
placement has allowed a relatively safe procedure
with fewer periprocedural complications (7–14).
We reviewed our experience with stent-assisted
angioplasty for medically refractory intracranial
vertebral and basilar artery stenoses, including the
intra- and periprocedural complications and long-
term angiographic and clinical outcomes.
Methods
Patients and Techniques
Between January 2000 and April 2004, 19 intracranial ver-
tebral or basilar arteries in 17 patients were treated by means
of stent-assisted angioplasty at our institutions.
The inclusion criteria for stent-assisted angioplasty were 1)
recurrent symptoms due to the vertebrobasilar artery stenosis
while being treated with optimal dosage of antiplatelet or
anticoagulation medication, and 2) angiographically proved
significant atherosclerotic stenoses (50%) that were respon-
sible for the symptoms. All cases that met the inclusion criteria
were included, unless the patient had refused treatment. There
were no cases of technical failure.
The angiographic findings and medical records were retro-
spectively reviewed for sex, age, comorbid medical conditions,
location of the lesion, degree of stenosis, Mori type, stenosis
after stent placement, type of stent, periprocedural complica-
tions during admission, clinical follow-up, and short- (12
months) and long-term (12 months) angiographic restenois
rates. Significant restenosis was defined as stenosis of greater
than 50%. Stenosis rates before and after stent-assisted angio-
plasty and at follow-up were compared by using a paired Stu-
dent t test. A probability of P less than .05 was considered
statistically significant. SPSS 10.0 statistical software was used.
Operative Technique
In general, the patients were premedicated with daily doses
of 100 mg of aspirin and 75 mg of clopidogrel (Plavix; Sanofi-
Synthelabo, Korea) for at least 3 days before the procedure. In
most patients, 2850 IU/0.3 mL of low-molecular-weight na-
droparin calcium (Fraxiparine; Sanofi-Synthelabo, Korea) was
injected subcutaneously two or three times per day during the
same period. The patient was fully awake during the procedure,
and the electrocardiogram, arterial oxygen saturation, and
blood pressure were appropriately monitored. Percutaneous
access was obtained via the right femoral artery and a 6F–7F
sheath was inserted. Baseline activated clotting time (ACT)
was obtained before the procedure. Then patients received
systemic heparinization and a bolus injection of 3000–5000 IU
of heparin just before starting the therapeutic procedure. A
booster of 1000 IU of heparin was administered every hour to
provide an ACT of longer than 250 seconds or twice the
baseline ACT throughout the entire procedure. A 6F–7F guid-
ing catheter (Envoy; Cordis Endovascular Corporation) was
positioned in the distal vertebral artery. After obtaining a
preliminary angiogram, the catheter was connected to a con-
tinuous saline flush. Preprocedural angiographic images were
then obtained in orthogonal planes.
Measurement of the stenosis was performed by the oper-
ator. The degree of stenosis was calculated as follows:
[1  (stenosis diameter)/normal diameter]  100. The stenosis
diameter was measured at the point of most severe stenosis,
and the normal diameter was measured proximal to the steno-
sis at a point that was judged to be normal. The stenotic
segment of the vertebral or basilar artery was then crossed with
a 0.014-inch microwire that was navigated to the P2 segment of
the posterior cerebral artery to ensure maximal support. Predi-
latation was not routinely perfomed owing to concerns of dis-
section and distal embolization. However, predilatation was
considered in severely stenotic cases (95% stenosis) or when
the diameter of the stenosed segment was considered to be
smaller than the profile of the stent catheter. The diameter of
the stent was chosen according to the diameter of the normal
proximal vessel. No attempt was made to undersize the stent. A
wide variety of stents were used in this series because of the
introduction of new stents with improved features during the
study period of 4 years. In some cases, the limitations in the
local availability of the stent contributed to the heterogenous
group of stents.
The coronary stent was advanced over the microwire and
positioned across the stenosis with angiographic confirmation.
In most cases, stent deployment was performed by using a
multistage inflation technique (Fig 1). In this technique, the
pressure of the balloon is increased in increments of 1 atmo-
sphere (atm) after the initial deployment of the stent at a
subnominal pressure. In other words, the pressure of the bal-
loon is slowly inflated to 4–5 atm, then subsequent angiography
is performed after deflating the balloon to identify any gap
between the distal end of the stent and the arterial wall. If any
gap is suspected at angiography, slow repeat inflation of the
balloon is performed until the gap between the distal end of the
stent and the parent artery has been eliminated. Then the distal
tip of the balloon is retrieved into the distal end of the stent. By
using the same technique, balloon inflations are repeated to the
point where the gap between the mid to proximal end of the
stent and the parent artery is eliminated. Balloon inflation
pressures did not exceed the burst pressure of the stent and
balloon. After satisfactory deployment of the stent, we waited
another 30 minutes to identify possible complications, includ-
ing acute in-stent thrombosis or vessel rupture. If there were no
complications at final angiography, we completed the entire
procedure. Immediately after stent placement, complete neu-
rologic examination was performed by a neurologist. After the
procedure, patients were medicated daily with 100 mg of aspi-
rin and/or 75 mg of clopidogrel indefinitely. In most patients,
2850 IU of fraxiparine was also administered subcutaneously
two or three times per day for at least 3 days. Written informed
consent was obtained from all patients or their representatives.
Results
The cases consisted of 10 men and seven women
(age range, 51–74 years; mean, 64 years) with 19
lesions. The locations of the lesions were intracranial
vertebral artery (n  13) and basilar artery (n  6).
The lesion Mori types were A in three, B in seven,
and C in nine. The mean preprocedure diameter
stenosis was 76.1 14.6%, which decreased significantly
to 1.3  2.8% after stent-assisted angioplasty (P 
.05). Predilatation was performed in six of 19 lesions.
Table 1 summarizes the patient characteristics.
Two partially overlapping stents were used in one
lesion (case 15) owing to the long length of the dis-
eased segment. In case eight (Fig 2), two partially
overlapping stents had to be used because the stent
was trapped at the proximal aspect of the nonpredi-
lated stenotic lesion. Thus, a second stent was de-
ployed, overlapping the distal aspect of the first stent
and covering the remainder of the lesion.
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Periprocedural Complications
Periprocedural complications occurred in two
(12%) of 17 cases. In case 1 (type B lesion), acute
in-stent thrombosis developed during the procedure.
Immediately after deployment of the stent, thrombus
formation within the stent struts was noted, and the
patient showed a rise in blood pressure from baseline
of 169/82 to 193/106 mm Hg. The patient also devel-
oped transient vertigo, nystagmus, and lateral gaze
limitations. Abciximab was injected intraarterially
(6-mg bolus  2 mg) and additional postprocedure
angioplasty was performed, resulting in complete re-
canalization. The neurologic symptoms subsided after
complete recanalization, and the patient did not de-
velop any new symptoms related to the procedure.
In case 4 (type C lesion), the patient developed
immediate postprocedural dizziness, diplopia, and
ataxia after stent deployment in the basilar artery.
Postprocedural MR imaging revealed multiple, newly
developed acute ischemic foci in the cerebellar hemi-
spheres. The patient made a gradual recovery of
symptoms.
No other patients developed any serious changes in
consciousness, blood pressure, pulse rate, electrocar-
FIG 1. Representative case of multistaged balloon inflation technique in a patient with left distal vertebral artery stenosis.
A, Pretreament angiogram shows a severely stenosed left distal vertebral artery at the site of posterior inferior cerebellar artery.
B, Angiogram shows the stent placed at the targeted lesion site; slow subnominal inflation (5 atm in this case) of the balloon was
performed, with special consideration given to preventing “dog boning” of the proximal and distal ends of the balloon. Angiogram (not
shown) was obtained to confirm the absence of a gap at the distal end of the stent.
C, Angiogram shows the balloon is carefully retrieved, with the proximal balloon marker (dotted arrow) placed outside the struts of the
proximal end of the stent (solid arrow).
D, The balloon was slowly inflated to or above the nominal pressure, with special consideration given to avoiding any gap in the middle
and proximal aspects of the stents. Repeat inflations were performed if any gap was visualized on the angiogram.
E, Final angiogram shows a well-positioned stent without gaps.
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diographic waves, or arterial oxygen saturation rates
during the procedure.
Clinical and Angiographic Follow-up
Clinical follow-up was available in all patients and
ranged from 6 to 45 months (mean follow-up, 17
months). During the follow-up period, three patients
(two type A lesions, one type B lesion) developed
transient ischemic attack symptoms (cases 2 and 7) or
minor stroke (case 8) at 3, 15, and 19 months after the
procedure, respectively. MR examinations revealed
newly developed ischemic lesions outside the verte-
brobasilar territory, thus the stroke symptoms were
regarded to be unassociated with the vertebrobasilar
artery lesion. One patient (6%, case 16 with a type C
lesion) developed thalamic intracranial hemorrhage 2
months after the procedure. This patient was given
warfarin after coronary stent placement for myocar-
dial infarction. Other patients showed improvement
of initial symptoms. Table 2 summarizes the fol-
low-up results.
Conventional angiographic follow-up was available
in 11 of 17 patients. Short-term angiographic fol-
low-up (range, 0.5–6 months; mean, 4.3 months) was
performed in five patients. Long-term angiographic
follow-up (range, 12–41 months; mean, 21 months)
was performed in six patients. No cases showed sig-
nificant restenosis of the stent-treated artery at short-
term follow-up. Three cases (cases 1, 2, and 3)
showed total patency without restenosis, and two
cases (cases 4 and 5) showed mild restenosis (10%
and 14%) from intimal hyperplasia. Both of the cases
showing mild restenosis were type C lesions. None of
the cases showed significant restenosis at long-term
follow-up as well. Total patency was observed in four
cases (cases 6, 7, 9, and 10) and mild restenosis (5%
and 10%) in two cases (cases 8 and 11). The mild
restenoses were observed in types A and C lesions,
respectively.
Discussion
In the midst of the rapid growing body of knowl-
edge and interest concerning the feasibility of stent-
assisted angioplasty for intracranial stenosis, the re-
sults of our case series offer further evidence in favor
of this new treatment option in patients with symp-
tomatic, medically refractory vertebrobasilar artery
stenosis. First, we have shown the feasibility of stent-
assisted angioplasty for verterbobasilar artery steno-
sis, with low periprocedural complication rates. Sec-
ond, we followed up these cases and have shown the
durability of the treatment outcome on short- and
long-term clinical as well as angiographic outcomes.
Previous reports on the results of stent-assisted
angioplasty for vertebrobasilar stenosis are relatively
limited. Since the initial pioneering case reports on
the technical feasibility of intracranial stent place-
ment for vertebrobasilar stenosis, a few case series
TABLE 1: Summary of patient characteristics and treatment
Case
No. Sex Age
Lesion
Location Comorbidities
Mori
Lesion
Type
Stenosis (%)
Predilatation
(mm)
Stent
(mm) ComplicationBefore After
1 F 58 BA H B 59 0 Maxxum 2.75/12 S660 2.75/18 Acute in-stent
thrombosis*
2 F 63 BA H, D, L A 65 5 Jo flex 4/16
IVA,Lt C 60 0 S670 3/24
3 F 65 IVA,Lt H B 62 10 S670 3.5/18
4 M 60 BA H C 82 0 Maverick 2/12 Cypher 2.5/13 Dizziness,
ataxia†
5 M 51 IVA,Rt H, D, S C 95 0 Maestro 1.5/20 Jo flex 2.5/23
6 M 70 IVA,Lt H, D, S, C A 90 0 S670 4/18
7 F 66 IVA,Lt H, D B 70 0 Jo flex 4/23
8 M 55 IVA,Lt H, D, L, S, C A 95 0 S660 2.5/9, 2.5/12‡
9 M 70 IVA,Rt H, C C 70 0 Jo bare 5/17
10 M 74 IVA,Rt H, D, S, M B 69 0 Ranger 2.5/20 AVE 3.5/12
11 F 60 BA H C 95 0 S670 3/18
12 M 69 BA H B 90 0 Jo flex 3.5/16
13 M 62 IVA,Lt H, L B 74 0 Larus 2.5/10 Jo Stent 3.0/12
14 F 65 BA H C 90 5 S670 3.5/24
IVA,Lt B 60 0 S670 4/24
15 F 76 IVA,Lt H, D, L, S C 80 0 S660 2.5/15,
S670 3/19§
16 M 68 IVA,Lt H, S, C C 50 5 S7 4/30
17 M 60 IVA,Lt H, L, S C 90 0 Maestro 1.5/20 Jo flex 3/19
Note.—IVA indicates intracranial vertebral artery; BA, basilar artery; H, hypertension; D, diabetes mellitus; L, hyperlipidemia; S, smoking; C,
coronary artery disease.
* Recanalized after intraarterial abciximab injection.
† Improved during hospitalization.
‡ First stent was trapped by the tight stenosis and had to be deployed proximal to the lesion site; thus, a second stent was used for distal angioplasty.
§ Two stents used for long length of the lesion.
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with follow-up results have been reported (10, 12,
14–22).
Gomez et al (16) reported the results of 12 cases of
stent-assisted angioplasty for basilar stenosis. The
clinical follow-up period ranged from 0.5 to 16
months (mean, 5.9 months). One patient had nonspe-
cific symptoms and another had a transient ischemic
attack. All other patients remained asymptomatic. In
the series by Mori et al (15), access failure was re-
ported in two of eight cases of intracranial verterbral
artery or basilar artey stent placement. Repeat arte-
riography of vertebrobasilar stent-treated lesions
(n  6) showed 6–25% restenosis (mean, 16%) at 3
months. No cerebrovascular event occurred during
and after the procedure and during the 8- and 13-
month clinical follow-up periods. Rasmussen et al
(17) reported their experience with intracranial ver-
tebrobasilar stent placement in eight patients. One
patient died on the day of the procedure because of a
massive subarachnoid hemorrhage. One patient expe-
rienced a transient encephalopathy. All remaining
patients were asymptomatic up to 8 months
postoperatively.
The early results of direct or conventional stent-
assisted angioplasty for intracranial vertebroplasty
stenosis by Levy et al (18) seemed somewhat less than
FIG 2. Case 8. A 55-year-old man with transient ischemic attack at presentation.
A, Initial left vertebral artery angiogram shows 95% stenosis of the intracranial vertebral artery.
B, Angiogram shows that the distal vertebral artery is straightened because of the stent-mounted catheter, and the lesion site is
displaced more cranially (arrow). Primary stent deployment was attempted with a S660 2.5/9 stent; however, the distal end of the stent
could not pass through the lesion site. Stent catheter was not retrieved because of concerns for acute thrombus formation. Notice the
compromised flow in the basilar artery due to the trapped stent catheter.
C, Magnified angiographic view. After deployment of the initial stent (solid arrows) and additional careful angioplasty, a second
stent-mounted catheter (dotted arrows) was navigated through the initial stent.
D, Magnified angiographic view. The second stent (dotted arrows) was deployed partially overlapping the initial stent (solid arrows)
and covering the distal aspect of the lesion.
E, Final angiogram shows no residual stenosis.
F, Seventeen-month follow-up angiogram shows the patent stent site without significant restenosis.
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satisfactory. Four (36%) of 11 patients died of pro-
cedure-related complications: two from vessel rup-
ture, one from brain death, and the last case from
pontine infarction. The remaining seven patients
showed symptom resolution, and angiographic fol-
low-up (mean, 4 months; range, 3 days to 12 months)
demonstrated good patency in five cases. One case
exhibited minimal intimal hyperplasia and the other
case exhibited 40% narrowing of the vessel lumen. In
later reports by Levy et al (19, 20), better outcome
was achieved by performing a staged stent-assisted
angioplasty for patients with vertebrobasilar stenoses.
In three patients, long-term angiographic follow-up
(23.2, 27, 30 months; mean, 26.7 months) was avail-
able. The postprocedure percentages of stenoses at
these periods were 24%, 16%, and 22%, respectively
(20).
In the recently published results of the Stenting of
Symptomatic Atherosclerotic Lesions in the Verte-
bral or Intracranial Arteries study (22), the technical
success rate for stent placement was 95% (58 of 61
cases) for vertebral or intracranial stenoses. Strokes
after stent placement occurred in 14% (three of 22
cases) of intracranial vertebrobasilar stenosis during a
1-year follow-up period. Although significant resteno-
sis ( 50% stenosis) occurred in 32.4% (12 of 37
cases) of intracranial arteries and 42.9% (six of 14
cases) of extracranial vertebral arteries at 6-month
follow-up angiography, only 39% (seven cases) were
symptomatic.
In our series, two cases (12%) of periprocedural
complications occurred. Case 1 (type B lesion) devel-
oped acute in-stent thrombosis immediately after
predilatation and stent deployment. In case 4 (type C
lesion), the patient developed dizziness and ataxia
immediately after the procedure. The possible causes
for these complications are, first, the disruption of the
atheromatous plaque from balloon inflation inducing
thrombosis formation; second, dissection of the artery
from predilatation or stent deployment; and, third,
presence of gap between the stent and arterial wall
causing acute or subacute thrombus formation. Per-
forator occlusion by the stent strut or by “snowplow-
ing effect” from the large-profile devices has been
proposed as a possible mechanism for poststent isch-
emic complications, but this seemed unlikely consid-
ering the findings of multiple cerebellar embolic in-
farct on follow-up MR images in the latter case (20,
23).
The acute in-stent thrombosis in the first case was
successfully managed with intraarterial injections
(6-mg bolus  2 mg) of abciximab and with angio-
plasty. Abciximab is the Fab fragment of a monoclo-
nal antibody directed against the platelet glycoprotein
IIb-IIIa receptor acting as a potent platelet inhibitor
(24). The most commonly used regimen consists of an
intravenous 0.25-mg/kg bolus injection and then a
continuous infusion of 0.125 mg/kg/min (maximum 10
mg/min) for 12 hours. The efficacy of abciximab has
been extensively documented in experimental as well
as clinical studies (25–27). Localized intraarterial in-
fusion of abciximab could theoretically allow a fast
recanalization with a small dose as in our case, and
such results have recently been reported for endovas-
cular procedures in the cerebral circulation (28, 29).
In terms of follow-up, we are not aware of any large
series of intracranial stent-assisted angioplasty cases
that include the results of long-term angiographic
follow-up. Our results show that the effects of stent-
assisted angioplasty for intracranial verterbrobasilar
stenosis are preserved in short- and long-term follow-
up. All cases showed clinical improvement, and none
of the 19 lesions showed significant restenosis on the
short- and long-term follow-up angiograms. These
results seem better than those of previously published
series. Experiences from coronary angioplasty and
TABLE 2: Clinical and angiographic follow-up results
Case No.
Clinical Follow-up Angiographic Follow-up
Duration (mo) Clinical Outcome Duration (mo) Restenosis (%)
1 10 Improved, residual dizziness 0.5 0
2 12 Improved, unrelated TIA at 3 mo 3 0*
3 11 Improved 6 0
4 10 Improved, residual dizziness 6 14
5 13 Improved 6 10
6 12 Improved 12 0
7 18 Improved, unrelated TIA at 15 mo 15 0
8 23 Improved, unrelated minor stroke at 19 mo 17 5
9 20 Improved 17 0
10 45 Improved, residual dizziness 25 0
11 41 Improved 41 10
12 6 Improved
13 7 Improved
14 41 Improved
15 7 Improved
16 10 Improved, thalamic ICH at 2 mo
17 6 Improved
Note.—TIA indicates transient ischemic attack; ICH, intracranial hemorrhage.
* Includes both verterbral artery and basilar artery lesions.
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stent placement have allowed a considerable body of
knowledge concerning the processes of restenosis (30,
31). Mechanisms involved in restenosis are elastic
recoil, negative remodeling, early thrombus forma-
tion, and neointimal hyperplasia with vascular smooth
muscle cells. With stent-assisted angioplasty, elastic
recoil and negative remodeling are virtually elimi-
nated as causes of restenosis. Restenosis in stents is
largely due to neointimal proliferation, which has a
strong tendency to occur in patients with diabetes
mellitus and in cases of small reference vessel diam-
eter and long stent length (30, 31).
Experience from coronary stent placement has
shown that the amount of initial luminal gain within
the stent-treated segment was a major determinant
for long-term luminal patency and also seemed to be
inversely correlated to the frequency of stent throm-
bosis (32, 33). Intravascular sonography in patients
who underwent coronary stent placement procedures
by using the traditional inflation techniques have
demonstrated a high frequency of incompletely ex-
panded stents despite an acceptable angiographic ap-
pearance (34). Thus, high-pressure inflation is often
performed in coronary stent placement to optimize
the stent apposition to the arterial wall (35). In the
case of intracranial vessels, the potential risk of rup-
ture from high-pressure inflations may be greater due
to a lack of surrounding supportive tissue in the sub-
arachnoid space. However, according to the coronary
experience, the stent-treated artery is believed to be
relatively immune from subsequent angioplasties by
the scaffolding properties of the previously deployed
stent. In the series by Alfonso et al (36), the risk of
arterial perforation from high-pressure inflations (14
atm) within the stent-treated segment of the coro-
nary arteries was very low, with a rate of 1.7% (three
of 170 cases).
In our series, we used a multistaged high-inflation
technique for stent deployment to optimize stent ex-
pansion and reduce the frequency of in-stent throm-
bosis and the restenosis rate. Regarding the discrep-
ancy between the proximal and distal diameters of
arteries and the irregular nature of the atheroscle-
rotic vessel, a single nominal pressure inflation may
not be sufficient in achieving an optimal stent appo-
sition. Thus, multistaged balloon inflations were per-
formed with the intention of optimally conforming
the stent configuration to the vascular anatomy. After
initial deployment of the stent, multistaged location-
adjusted slow balloon inflations, with multiple interim
angiograms, were performed to eliminate gaps, thus
resulting in a tailored apposition of the stent to the
arterial anatomy. The initial target for gap elimina-
tion was the distal end of the stent, and after achiev-
ing satisfactory apposition at the distal end, the bal-
loon was slightly retrieved into the stent. The reason
for such multistaged, location-adjusted inflations was
that the distal vessel diameter is usually smaller than
the proximal vessel diameter, and multiple inflations
disregarding the discrepancy could be the cause of
dissection or perforation, especially at the distal end.
Inflations were always performed in a very slow man-
ner to prevent dissection from the “dog-bone” phe-
nomenon at the distal and proximal ends of the bal-
loon. Balloon inflation pressures not exceeding the
burst pressure of the balloon and stent and prepara-
tion of extra balloons and stents for emergent arterial
hemostasis in case of rupture were also necessary for
a safer procedure. These technical innovations may
have been key to the favorable periprocedural and
long-term follow up results.
Predilatation was not routinely performed in our
series (direct stent placement in 13 of 19 lesions),
because it carries a higher risk of dissection and distal
emboli from plaque disruption (21). This caused a
problem in one case (Fig 2, case 8), in which the stent
was trapped by the tight stenosis (95%) and could not
cross the stenosed segment. A second stent had to be
deployed, overlapping the initial stent; the patient did
not develop any neurologic deficits associated with
the procedure. These results seem to contradict the
finding of Levy et al in which direct stent placement
was associated with dense quadriparesis in two of four
cases, as mentioned above. They explained that the
high rates of complications were due to embolic
shower or the “snowplowing effect” of the high-pro-
file stents. Their recommendations were to perform a
staged submaximal angioplasty followed by a second
session stent placement to augment the lumen of the
parent vessel while minimizing the risk of plaque
rupture, and also to afford protection against distal
embolization of plaque debris, especially for unstable
(recently symptomatic), ulcerated, or high-grade ste-
nosis (20). In view of our favorable results, however,
we believe that direct or conventional stent placement
with a multistaged inflation technique is a feasible
treatment option. It may be more advantageous com-
pared with the multistaged sessions in terms of time
and cost.
The outcomes of stent-assisted angioplasty for the
Mori type C lesions (n  9) in our series were also
satisfactory, with only one case showing periproce-
dural complications (case 4). Nevertheless, three of
the four cases of mild restenosis were type C lesions.
For this type of lesion, an optimal treatment method
in terms of equipment and technique should be
sought and further emphasis on follow-up should be
considered.
Conclusion
Stent-assisted angioplasty for symptomatic, medi-
cally refractory intracranial vertebrobasilar stenosis is
a technically feasible treatment option with a rela-
tively low complication rate. Also, the treatment re-
sults seem to be sustained in the long-term clinical
and angiographic follow-up studies. Randomized
controlled trials are necessary to further validate this
treatment option.
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